Lyell Immunopharma (LYEL) Consolidated Net Income (2020 - 2026)
Lyell Immunopharma (LYEL) posted Consolidated Net Income of -$103.2 million for Q1 2026, up 28.67% sequentially from -$144.7 million in Q4 2025, and up 19.91% YoY from -$86.1 million in Q1 2025.
Lyell Immunopharma (LYEL) Consolidated Net Income (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported Consolidated Net Income for 7 years, with the latest figure at -$103.2 million in Q1 2026.
- Quarterly Consolidated Net Income rose 19.91% year-over-year to -$103.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$465.5 million (up 50.67% YoY) and the FY2025 annual result came in at -$286.5 million, up 60.08% from the prior year.
- Consolidated Net Income advanced to -$103.2 million in Q1 2026 per LYEL's latest filing, from -$144.7 million in the prior quarter.
- Over five years, Consolidated Net Income peaked at -$13.6 million in Q4 2022 and troughed at -$561.1 million in Q4 2024.
- A 5-year average of -$149.6 million and a median of -$124.4 million in 2024 frame the typical range for Consolidated Net Income.
- The sharpest annual moves came in 2022 and 2023: Consolidated Net Income jumped 92.31% in 2022, then sank 2163.17% in 2023.
- Over 5 years, Consolidated Net Income stood at -$13.6 million in 2022, then tumbled by 2163.17% to -$306.8 million in 2023, then plunged by 82.85% to -$561.1 million in 2024, then surged by 74.21% to -$144.7 million in 2025, then climbed by 28.67% to -$103.2 million in 2026.
- According to Business Quant data, Consolidated Net Income over the past three periods registered -$103.2 million, -$144.7 million, and -$102.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - | -102.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -102.94 Mn |
| Mar 31, 2026 | -103.22 Mn |
| Dec 31, 2025 | -144.69 Mn |
| Sep 30, 2025 | -102.17 Mn |
| Jun 30, 2025 | -115.47 Mn |
| Mar 31, 2025 | -128.88 Mn |
| Dec 31, 2024 | -561.06 Mn |
| Sep 30, 2024 | -124.41 Mn |
| Jun 30, 2024 | -129.48 Mn |
| Mar 31, 2024 | -74.91 Mn |
| Dec 31, 2023 | -306.84 Mn |
| Sep 30, 2023 | -70.05 Mn |
| Jun 30, 2023 | -90.81 Mn |
| Mar 31, 2023 | -83.31 Mn |
| Dec 31, 2022 | -13.56 Mn |
| Sep 30, 2022 | -188.38 Mn |
| Jun 30, 2022 | -129.98 Mn |
| Mar 31, 2022 | -175.37 Mn |
| Dec 31, 2021 | -176.32 Mn |
| Sep 30, 2021 | -60.65 Mn |